AlaRS Monoklonaler Antikörper

• Featured Product
• KD/KO Validated

AlaRS Monoklonal Antikörper für IF/ICC

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human, Maus, Ratte

Anwendung

IF/ICC

Konjugation

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

1C8H3

Kat-Nr. : CL488-67909

Synonyme

AARS, 1C8H3, EC:6.1.1.7, Alanyl-tRNA synthetase, Alanine--tRNA ligase, cytoplasmic

---

• 

  IF Staining of A431 using CL488-67909

  Immunofluorescent analysis of (-20°C Methanol) fixed A431 cells using CoraLite® Plus 488 AlaRS antibody (CL488-67909, Clone: 1C8H3 ) at dilution of 1:200.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF/ICC: A431-Zellen

Empfohlene Verdünnung

• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL488-67909 bindet in IF/ICC AlaRS und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: AlaRS fusion protein Ag11151
• Vollständiger Name: alanyl-tRNA synthetase
• Berechnetes Molekulargewicht: 968 aa, 107 kDa
• Beobachtetes Molekulargewicht: 107 kDa
• GenBank-Zugangsnummer: BC011451
• Gene symbol: AlaRS
• Gene ID (NCBI): 16
• Konjugation: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Form: Liquid
• Reinigungsmethode: Protein-G-Reinigung
• Lagerungspuffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

AARS(alanyl-tRNA synthetase) is also named as AlaRS(alanine tRNA ligase 1, cytoplasmic), renal carcinoma antigen NY-REN-42 and belongs to the class-II aminoacyl-tRNA synthetase family. It can interpret the RNA code and attach specific aminoacids to the tRNAs that contain the cognate trinucleotide anticodons. AARS consists of three domains: the N-terminal catalytic domain, the editing domain and the C-terminal C-Ala domain. The editing domain removes incorrectly charged amino acids, while the C-Ala domain, along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs(PMID:19661429).